Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACXP NYSE:ANVS NASDAQ:ITRM NASDAQ:PLUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$0.45+0.2%$0.44$0.30▼$2.75$13.30M-1.231.69 million shs709,675 shsANVSAnnovis Bio$2.66-5.4%$2.45$1.11▼$11.69$54.76M1.57383,936 shs475,137 shsITRMIterum Therapeutics$0.92-6.5%$0.98$0.81▼$3.02$39.20M2.791.09 million shs1.81 million shsPLURPluri$4.95-8.5%$4.85$3.33▼$7.13$42.58M0.7920,793 shs6,705 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals+4.27%-10.02%-45.29%+21.35%-82.86%ANVSAnnovis Bio+1.18%-2.08%+6.62%+127.42%-77.37%ITRMIterum Therapeutics+1.03%-9.26%0.00%-9.26%-24.03%PLURPluri+7.13%0.00%+27.59%+37.83%-5.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACXPAcurx Pharmaceuticals2.6118 of 5 stars3.53.00.00.03.31.70.0ANVSAnnovis Bio1.5854 of 5 stars3.51.00.00.00.61.70.6ITRMIterum Therapeutics2.0793 of 5 stars3.53.00.00.03.30.00.0PLURPluri3.5764 of 5 stars3.55.00.00.03.33.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACXPAcurx Pharmaceuticals 3.00Buy$8.001,677.78% UpsideANVSAnnovis Bio 3.00Buy$18.00577.20% UpsideITRMIterum Therapeutics 3.00Buy$9.00881.89% UpsidePLURPluri 3.00Buy$12.00142.42% UpsideCurrent Analyst Ratings BreakdownLatest ACXP, ITRM, ANVS, and PLUR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $12.006/2/2025PLURPluriIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$12.006/2/2025PLURPluriAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.005/15/2025ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$8.005/15/2025ANVSAnnovis BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $17.005/8/2025ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$9.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACXPAcurx PharmaceuticalsN/AN/AN/AN/A$0.03 per shareN/AANVSAnnovis BioN/AN/AN/AN/A$0.67 per shareN/AITRMIterum TherapeuticsN/AN/AN/AN/A($0.15) per shareN/APLURPluri$330K118.05N/AN/A$1.00 per share4.95Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACXPAcurx Pharmaceuticals-$14.10M-$0.700.00N/AN/AN/A-526.78%-223.78%8/8/2025 (Estimated)ANVSAnnovis Bio-$24.59M-$2.160.00N/AN/AN/A-300.56%-193.50%8/13/2025 (Estimated)ITRMIterum Therapeutics-$24.77M-$0.99N/A∞N/AN/AN/A-71.37%8/13/2025 (Estimated)PLURPluri-$20.89M-$5.53N/A∞N/A-2,563.29%-4,191.91%-85.40%9/16/2025 (Estimated)Latest ACXP, ITRM, ANVS, and PLUR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ANVSAnnovis Bio-$0.36N/AN/AN/AN/AN/A8/13/2025Q2 2025ITRMIterum Therapeutics-$0.13N/AN/AN/AN/AN/A8/8/2025Q2 2025ACXPAcurx Pharmaceuticals-$0.10N/AN/AN/AN/AN/A5/13/2025Q1 2025ANVSAnnovis Bio-$0.47-$0.32+$0.15-$0.32N/AN/A5/13/2025Q1 2025ITRMIterum Therapeutics-$0.14-$0.14N/A-$0.14N/AN/A5/13/2025Q3 2025PLURPluriN/A-$0.94N/A-$0.94N/A$0.43 million5/12/2025Q1 2025ACXPAcurx Pharmaceuticals-$0.14-$0.11+$0.03-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACXPAcurx PharmaceuticalsN/AN/AN/AN/AN/AANVSAnnovis BioN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/APLURPluriN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACXPAcurx PharmaceuticalsN/A1.931.93ANVSAnnovis BioN/A10.6810.68ITRMIterum TherapeuticsN/A3.723.58PLURPluri51.654.814.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACXPAcurx Pharmaceuticals11.53%ANVSAnnovis Bio15.83%ITRMIterum Therapeutics9.21%PLURPluri16.59%Insider OwnershipCompanyInsider OwnershipACXPAcurx Pharmaceuticals26.00%ANVSAnnovis Bio20.80%ITRMIterum Therapeutics9.20%PLURPluri25.93%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACXPAcurx Pharmaceuticals329.63 million21.92 millionOptionableANVSAnnovis Bio319.49 million15.43 millionOptionableITRMIterum Therapeutics1040.00 million36.32 millionNot OptionablePLURPluri1507.87 million5.83 millionOptionableACXP, ITRM, ANVS, and PLUR HeadlinesRecent News About These CompaniesPluri (NASDAQ:PLUR) Trading Down 4% - Should You Sell?July 9, 2025 | americanbankingnews.comPluri Inc. director not re-elected, Nasdaq compliance cure period grantedJuly 5, 2025 | investing.comInsider Buying: Pluri Inc. (NASDAQ:PLUR) Director Purchases 976,139 Shares of StockJuly 2, 2025 | insidertrades.comAlliance Global Partners Initiates Coverage of Pluri (PLUR) with Buy RecommendationJune 2, 2025 | msn.comPluri Inc. reschedules 2025 annual meetingMay 27, 2025 | investing.comBrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical TrialsMay 27, 2025 | prnewswire.comBrainstorm Cell Therapeutics outlines imminent Phase 3b ALS trial launch following FDA clearance and expanded manufacturing plansMay 19, 2025 | msn.comPluri Inc.: Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.May 16, 2025 | finanznachrichten.dePluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market ExpansionMay 16, 2025 | tmcnet.comPluri: Fiscal Q3 Earnings SnapshotMay 13, 2025 | timesunion.comTPluri Inc. acquires majority stake in Kokomodo Ltd.April 30, 2025 | uk.investing.comPluri acquires 71% stake in KokomodoApril 29, 2025 | foodbusinessnews.netFPluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.April 28, 2025 | globenewswire.comPluri Inc. enters agreement, issues pre-funded warrantsApril 27, 2025 | investing.comUkraine gains access to Israeli anti-radiation drug amid nuclear threatsApril 21, 2025 | msn.comUkraine prepares for nuclear emergency - Israel to help save thousandsApril 21, 2025 | msn.comIn case of a nuclear event, Ukraine to use Israeli placenta-based emergency treatmentApril 20, 2025 | msn.comInnovative Treatment Aims to Protect Ukrainians from Nuclear Radiation ThreatApril 17, 2025 | themunicheye.comTPluri announces USPTO issued patent covering its immune cell expansion techApril 12, 2025 | markets.businessinsider.comPluri’s immune cell expansion technologies gain patentsApril 11, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACXP, ITRM, ANVS, and PLUR Company DescriptionsAcurx Pharmaceuticals NASDAQ:ACXP$0.45 +0.00 (+0.22%) Closing price 04:00 PM EasternExtended Trading$0.45 0.00 (-0.89%) As of 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Annovis Bio NYSE:ANVS$2.66 -0.15 (-5.41%) Closing price 03:59 PM EasternExtended Trading$2.70 +0.04 (+1.58%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Iterum Therapeutics NASDAQ:ITRM$0.92 -0.06 (-6.47%) Closing price 04:00 PM EasternExtended Trading$0.92 +0.00 (+0.37%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Pluri NASDAQ:PLUR$4.95 -0.46 (-8.50%) Closing price 03:34 PM EasternExtended Trading$4.66 -0.29 (-5.86%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
